GSK Jumps Into Growing China R&D Space
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline has joined a growing list of big pharma companies expanding in China, launching a research and development center based in Shanghai, the company announced May 24
You may also be interested in...
Emerging Markets On Executives’ Minds At JPM15
Several top executives from major multinationals made comments on emerging market strategies at the JP Morgan Healthcare Conference in San Francisco Jan. 12-15 that piqued the interest of PharmAsia News. Among them, GSK said it was looking for a broad product portfolio, Lilly noted it had doubled its sales in China and Becton Dickinson highlighted the need to develop targeted products.
Exclusive: GSK Head Of Research Due In Shanghai Thursday To Begin Detailed Audit Of China R&D Operations
In an internal email, Patrick Vallance, GlaxoSmithKline’s president for pharmaceutical R&D, says he will arrive in Shanghai June 13 to help look for answers on how a paper authored by members of GSK’s China R&D unit misrepresented data. The incident has led to the dismissal of China R&D head Jingwu Zang, who spoke to PharmAsia News about the swirling controversy.
GSK Says Paper Published In Nature Medicine By Company Scientists To Be Retracted
GSK confirms dismissal of R&D China Head Jingwu Zang. GSK internal communication seen by PharmAsia News alleges “disturbing efforts” by employees to undermine an internal investigation into a paper on preclinical research; GSK suspends programs related to IL-7 receptor signaling pathway.